AF
Therapeutic Areas
Century Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CNTY-101 | Relapsed/Refractory B-cell Malignancies (e.g., NHL, CLL) | Phase 1 |
| CNTY-102 | Relapsed/Refractory AML & other CD123+ hematologic cancers | Preclinical |
| CNTY-107 | Multiple Myeloma | Preclinical |
| iT Cell Programs | Solid Tumors | Discovery/Preclinical |
| Autoimmune Programs | Undisclosed Autoimmune Diseases | Discovery |
Leadership Team at Century Therapeutics
LF
Lalo Flores, Ph.D.
Chief Executive Officer
O(
Osvaldo (Oz) Flores, Ph.D.
President & Chief Operating Officer
GR
Greg Russotti, Ph.D.
Chief Technology Officer
J(
Joseph (Joe) Jimenez
Chair of the Board of Directors
BF
Bardia Farahbod, M.D.
Chief Medical Officer